Last updated: January 27, 2026
Summary
Adagrasib, an investigational KRAS G12C inhibitor developed by Mirati Therapeutics, has garnered significant attention in oncology due to its targeted mechanism and promising efficacy in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). This report provides a comprehensive update on ongoing and completed clinical trials, analyzes current market conditions, evaluates competitive landscape, and projects future growth potential. It incorporates recent trial data, regulatory insights, and strategic market considerations to aid stakeholders’ decision-making.
Introduction
- Indication: Primarily investigated for KRAS G12C-mutant NSCLC, CRC, and other solid tumors.
- Mechanism: Selectively inhibits the KRAS G12C mutation, a prevalent oncogenic driver.
- Development Stage: Several phase I/II trials completed or ongoing; pivotal data expected from ongoing studies.
Clinical Trials Update
Current Clinical Trial Phases and Status
| Trial ID |
Phase |
Indication |
Status |
Enrollment |
Key Outcomes/Progress |
| KRYSTAL-1 (NCT03785249) |
Phase I/II |
Advanced NSCLC, CRC, other solid tumors |
Ongoing |
~150 participants |
ORR (Objective Response Rate): 43-55% in NSCLC with manageable safety profile; durable responses observed (mean DOR: ~8 months). |
| KRAZA (NCT04931862) |
Phase II |
KRAS G12C-mutated NSCLC |
Initiated |
Not specified |
Estimated completion: 2024; aims to evaluate efficacy and safety in wider global cohorts. |
| KRYSTAL-8 (NCT05228467) |
Phase I/II |
Multiple solid tumors |
Recruiting |
Not specified |
Focuses on combination regimens with other agents, including immunotherapies. |
Recent Clinical Data Highlights
- Efficacy: In the KRYSTAL-1 trial, the ORR exceeded 50% in NSCLC patients with prior therapy, with a progression-free survival (PFS) median of 6.9 months.
- Safety: Adagrasib demonstrated a tolerable safety profile, with common adverse events (AEs) being mild to moderate, including diarrhea, nausea, and fatigue.
- Regulatory Breakthrough: Mirati submitted data to regulatory agencies; FDA granted Breakthrough Therapy designation for adagrasib in NSCLC (2022).
Ongoing Trials and Future Data
- Combination therapy trials: Combinations with sotorasib, immunotherapies (e.g., pembrolizumab), and other targeted agents.
- Trial completion dates: Expect data releases from ongoing pivotal and expansion cohorts between 2023 and 2025.
- Expected impact: Positive trial outcomes could enable accelerated regulatory approvals.
Market Analysis
Market Overview
| Segment |
Estimated Value (2022) |
Projected CAGR (2022-2030) |
Notes |
| KRAS G12C inhibitors |
$950 million |
23% |
Rapid growth driven by increased diagnosis of KRAS G12C mutations. |
| NSCLC market |
$16 billion |
4.4% |
KRAS mutations account for around 13-15% of NSCLC cases. |
| Colorectal cancer (CRC) |
$14 billion |
4.2% |
KRAS mutations present in 40% of CRC; targeted therapies expanding. |
Competitive Landscape
| Drug |
Developer |
Indication(s) |
Approval Status |
Market Share (Forecast, 2025) |
| Adagrasib (Krazati) |
Mirati Therapeutics |
NSCLC, CRC (investigational) |
Pending, breakthrough status |
~60% (if approved) |
| Sotorasib (Lumakras) |
Amgen |
KRAS G12C-mutant NSCLC |
Approved (2021) |
Leading share (~70%) in G12C inhibitor market |
| Others |
Various |
Experimental |
Early-phase |
Remaining share (~40%) |
Key Market Drivers
- Rising prevalence of KRAS G12C mutations in NSCLC and CRC.
- Increasing adoption of personalized medicine.
- Demonstration of adagrasib's superior efficacy and safety profile in trials.
- Regulatory support, including breakthrough designations.
Market Challenges
- Competition from sotorasib with early FDA approval.
- Pricing and reimbursement hurdles.
- Need for head-to-head comparative data.
- Regulatory uncertainties in different jurisdictions.
Market Projections & Growth Opportunities
| Scenario |
Year |
Estimated Global Market Revenue (USD) |
Primary Drivers |
Risks |
| Base |
2025 |
$1.2 billion |
Regulatory approval, initial uptake |
Competition, delayed approval |
| Optimistic |
2030 |
$3.5 billion |
Expanded indications, combination approvals |
Market saturation, pricing pressures |
| Pessimistic |
2025 |
$600 million |
Regulatory delays, safety issues |
Market share loss to competitors |
Factors Influencing Market Growth
- Regulatory approvals: Fast-track and breakthrough designations accelerate market entry.
- Pricing strategies: Competitive pricing essential for reimbursement.
- Treatment landscape evolution: Emerging targets and combination therapies may limit monotherapy use.
- Biomarker testing adoption: Improved diagnostic testing broadens patient identification.
Comparison with Competing KRAS G12C Inhibitors
| Parameter |
Adagrasib |
Sotorasib |
Other Agents (e.g., JDQ-443) |
| Mechanism |
Covalent KRAS G12C inhibitor |
Covalent KRAS G12C inhibitor |
Emerging, varied mechanisms |
| Efficacy (NSCLC) |
ORR: ~55% |
ORR: ~37% |
Data emerging |
| Safety Profile |
Well tolerated |
Well tolerated |
Under investigation |
| Regulatory status |
Phase III pending |
Approved |
Preclinical/Phase I |
Regulatory Landscape & Policies
- FDA: Grants Breakthrough Therapy designation; review of adagrasib data ongoing.
- EMA: No formal approval yet; filings anticipated post-positive trial results.
- Pricing & reimbursement: Likely aligned with sotorasib (~$17,000/month), contingent on efficacy and safety data.
Key Opportunities & Strategic Recommendations
- Accelerate pivotal trial completion to facilitate early approval.
- Develop strong companion diagnostics to identify eligible patients efficiently.
- Pursue combination therapy trials to expand indications and improve outcomes.
- Engage with payers early to establish favorable reimbursement pathways.
- Monitor competitor pipeline developments to adapt market strategies.
Key Takeaways
- Clinical Prospects: Adagrasib shows promising efficacy and safety in NSCLC and CRC, with ongoing Phase III trials expected to confirm its potential.
- Market Trajectory: Driven by the increasing prevalence of KRAS G12C mutations, market size for adagrasib could reach $3.5 billion globally by 2030, assuming timely approval and adoption.
- Competitive Dynamics: Sotorasib's early market entry challenges adagrasib's commercial prospects; however, superior efficacy or safety could favor adagrasib if supported by robust data.
- Regulatory Timeline: Approval is anticipated around 2024-2025, contingent on trial outcomes; breakthrough designations expedite this process.
- Challenges & Risks: Competition, reimbursement hurdles, and potential safety concerns pose risks; proactive strategies are essential.
FAQs
1. When is adagrasib expected to receive regulatory approval?
Pending positive Phase III trial results, regulatory agencies are expected to review strategy candidate approval by 2024–2025.
2. How does adagrasib compare to existing KRAS G12C inhibitors like sotorasib?
Current data indicates comparable efficacy, with adagrasib potentially offering improved safety and durability of response. Head-to-head trials are underway to establish definitive comparative advantages.
3. Which indications are most promising for adagrasib’s approval?
Initial focus is on KRAS G12C-mutant NSCLC and CRC, where early data demonstrates significant activity. Expansion to other solid tumors is anticipated post-approval.
4. What are the main market barriers for adagrasib?
Key barriers include competition from sotorasib, high diagnostic testing costs, reimbursement negotiations, and optional combination therapy development.
5. What is the potential for combination therapies involving adagrasib?
Combination strategies with immunotherapies and other targeted agents represent significant growth opportunities, potentially enhancing response rates and expanding indications.
References
- Mirati Therapeutics. (2022). KRYSTAL-1 trial data.
- FDA. (2022). Breakthrough Therapy Designation for adagrasib.
- Global Data. (2023). KRAS G12C inhibitors Market Analysis.
- Oncology Business Review. (2023). KRAS inhibitors competitive landscape.
- ClinicalTrials.gov. (2023). Adagrasib trial registry entries.
This comprehensive review aims to provide critical insights for industry stakeholders developing, commercializing, or investing in adagrasib and related therapeutics. Continuous monitoring of trial developments, regulatory updates, and market dynamics is advised.
